• Skip to main content
  • Skip to secondary menu
  • Skip to footer

Press Media Release

press release distribution

  • Submit a Press Release
  • Market Wire
  • Make a Contribution
  • About
    • Template for press/media release
    • How to structure your press release for maximum impact
    • Crafting effective headlines and leads to capture journalists’ attention
    • Understanding the dos and don’ts of writing press releases
    • Tips for writing clear, concise, and informative press releases
    • The importance of understanding your audience before writing a press release
    • Best practices for incorporating quotes and statistics in your press release
    • Writing effective boilerplates and about us sections for press releases
    • Identifying key media contacts and building relationships with journalists
    • Writing for different types of media, such as print, online, and social media
    • Measuring the success of your press release and tracking media coverage
  • Contact

Moderna Announces Amendment to Current Supply Agreement with United Kingdom Government for an Additional 2 Million Doses of mRNA Vaccine Against COVID-19 (mRNA-1273)

November 29, 2020 By admin Leave a Comment

UK government has now secured 7 million doses of mRNA-1273

Agreement reflects Moderna’s commitment to make its vaccine available in multiple countries

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced a supply agreement with the UK government for an additional 2 million doses of mRNA-1273, Moderna’s vaccine candidate against COVID-19, to the United Kingdom beginning in March 2021. The UK government has now secured 7 million doses of mRNA-1273. This confirmation comes as the UK continues its efforts to secure access to safe and effective COVID-19 vaccines by establishing a broad portfolio of the most promising vaccines.

“We appreciate the collaboration with the UK government as with many other governments and other key partners around the world,” said Stéphane Bancel, Chief Executive Officer of Moderna. “For almost a decade, Moderna has invested in creating and developing a novel platform for designing and manufacturing a new class of mRNA-based vaccines. We are proud of the progress on mRNA-1273 we have made to date including the positive interim analysis from our Phase 3 COVE study.”

On November 16, Moderna announced that the independent, NIH-appointed Data Safety Monitoring Board (DSMB) for the Phase 3 study of mRNA-1273, its vaccine candidate against COVID-19, has informed Moderna that the trial has met the statistical criteria pre-specified in the study protocol for efficacy, with a vaccine efficacy of 94.5%. This study, known as the COVE study, enrolled more than 30,000 participants in the U.S. and is being conducted in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), and the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services.

On October 27, 2020, Moderna received confirmation that the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom started the rolling review process of mRNA-1273.

Moderna continues to scale up its global manufacturing to be able to deliver approximately 500 million doses per year and possibly up to 1 billion doses per year, beginning in 2021. The Company is working with its strategic manufacturing partners, Lonza of Switzerland and ROVI of Spain, for manufacturing and fill-finish outside of the United States. This is a dedicated supply chain to support Europe and countries other than the United States that enter into purchase agreements with Moderna. To learn more about Moderna’s work on mRNA-1273, visit www.modernatx.com/COVID19.

About mRNA-1273
mRNA-1273 is an mRNA vaccine against COVID-19 encoding for a prefusion stabilized form of the Spike (S) protein, which was co-developed by Moderna and investigators from NIAID’s Vaccine Research Center. The first clinical batch, which was funded by the Coalition for Epidemic Preparedness Innovations, was completed on February 7, 2020 and underwent analytical testing; it was shipped to the NIH on February 24, 42 days from sequence selection. The first participant in the NIAID-led Phase 1 study of mRNA-1273 was dosed on March 16, 63 days from sequence selection to Phase 1 study dosing. On May 12, the FDA granted mRNA-1273 Fast Track designation. On May 29, the first participants in each age cohort: adults ages 18-55 years (n=300) and older adults ages 55 years and above (n=300) were dosed in the Phase 2 study of mRNA-1273. On July 8, the Phase 2 study completed enrollment.

Results from the second interim analysis of the NIH-led Phase 1 study of mRNA-1273 in the 56-70 and 71+ age groups were published on September 29 in The New England Journal of Medicine. On July 28, results from a non-human primate preclinical viral challenge study evaluating mRNA-1273 were published in The New England Journal of Medicine. On July 14, an interim analysis of the original cohorts in the NIH-led Phase 1 study of mRNA-1273 was published in The New England Journal of Medicine. mRNA-1273 currently is not approved for use by any regulatory body.

BARDA is supporting the continued research and development of mRNA-1273 with $955 million in federal funding under Contract no. 75A50120C00034. BARDA is reimbursing Moderna for 100 percent of the allowable costs incurred by the Company for conducting the program described in the BARDA contract. The U.S. government has agreed to provide up to $1.525 billion to purchase supply of mRNA-1273 under U.S. Department of Defense Contract No. W911QY-20-C-0100.

Filed Under: Press Release

Reader Interactions

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Footer

Recent Posts

  • Webinar: Agile Software Development Metrics and Measurement
  • VPN Workshop Program Offers Comprehensive Training on VPN Technology
  • New Technology Job Board Launches to Connect Job Seekers with Top Employers
  • Media Release: Israelis Protest Proposed Judicial Reforms Amid Knesset Debate
  • S3H.com to Showcase Cutting-Edge Technology at MWC Barcelona 2023
  • MarketAnalysis.com Rates Fastly Shares as “Sell”
  • MarketAnalysis.com Rates Cloudflare Shares as “Strong Buy”
  • Technologies.org supports the Data Science and Literacy Act of 2023
  • AppCoding.com Won Order to Develop of Travel Apps Suite After Participating in Travel Tradeshow IMTM 2023
  • IsraelNews.org to Attend and Cover IMTM 2023, The Premier International Tourism Fair in Israel

Media Partners

  • VPNW.com
  • OPINT
  • Digital Market
Will the RESTRICT Act Impact VPN Usage?
Comparing different VPN protocols
Creating a VPN for IoT devices
Building a VPN using cloud services
Analyzing VPN security vulnerabilities
Agile Requirements Gathering and User Story Mapping
OPINT: Exploring the Intersection of Operational Intelligence and Gaming in the Defense Industry
Russia says will cut crude production by 5% next month
President Xi Jinping’s long-term economic ambitions are out of reach
The South China Sea (SCS) and East China Sea (ECS) are becoming a major area of competition between the US and China
Developing a Business Concept for Posters.org: Personalized Artwork with AI-Generated Designs
Sortium, a Generative AI & Web3 entertainment technology provider, has been accepted into the UC Berkeley Blockchain Xcelerator program
Calendarial.com Presents: 7 Smart Ways to Monetize Your Event Promoting Website
How to build a successful Instagram channel
7 Proven Strategies for Selling Your Domain Name Quickly and Effectively

Media Partners

  • Media Instances
  • PXEF.com
  • Marketing Development
Scaling Agile for Distributed Teams
Media instances in gaming
Media Tycoons: The Powers Behind the Scenes
The Art of Blacksmithing: A Lost Craft
The History of the Ostrich-Feather Fan
The Woman in Yellow
Mexican Maya art style abstract painting
The Aesthetical Wonder of Almond Tree Flowering
Poster Ideas
Appy Pie Design Launches AI Text to Image Generator for Easy Visual Content Creation
Unleashing the Potential of Ghost Commerce: A Guide to Making Money in the Digital World
Unlocking the Power of Side Hustles: How to Earn Extra Income and Pursue Your Passion
Conversational commerce: changing the way businesses approach marketing
The Importance of Personalization in Digital Marketing
How to Write Inclusive Documentation

Copyright © 2022 PressMediaRelease.com

Sponsored by Exclusive Domains

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
Cookie SettingsAccept
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT